E-Book, Englisch, 253 Seiten, Format (B × H): 152 mm x 229 mm
Reihe: ISSN
Vande Woude / Klein Advances in Cancer Research
1. Auflage 2009
ISBN: 978-0-08-092233-1
Verlag: Academic Press
Format: EPUB
Kopierschutz: 6 - ePub Watermark
E-Book, Englisch, 253 Seiten, Format (B × H): 152 mm x 229 mm
Reihe: ISSN
ISBN: 978-0-08-092233-1
Verlag: Academic Press
Format: EPUB
Kopierschutz: 6 - ePub Watermark
Advances in Cancer Research provides invaluable information on the exciting and fast-moving field of cancer research. Here, once again, outstanding and original reviews are presented on a variety of topics, including nitric oxide-induced apoptosis in tumor cells, detection of minimal residual disease, immunity to oncogenetic human papilloma viruses, and modeling prostate cancer in the mouse.
Zielgruppe
Researchers and students in the basic and clinical sciences of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology, and molecular biology.
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
1;Front Cover;1
2;Advances in Cancer Research;4
3;Copyright;5
4;Contents;6
5;Contributors;10
6;Chapter 1: Ras Signaling and Therapies;12
6.1;I. Introduction: The Ras Superfamily and Their Regulators;12
6.2;II. The Raf/MAPK Pathway;14
6.3;III. Ras and the PI3K Pathway;16
6.4;IV. Cellular Signals that Block Ras Pathways;18
6.5;V. Ras and Neurofibromatosis;22
6.6;VI. Therapeutic Opportunities;23
6.7;References;25
7;Chapter 2: PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis;30
7.1;I. Introduction of PI3K/PTEN Signaling Pathway;31
7.2;II. Angiogenesis Regulated by VEGF, Angiopoietins, and PI3K Activation;35
7.3;III. Genetic Aberrations of PI3K, PTEN, and AKT in Cancer;38
7.4;IV. Roles of PI3K and AKT in Regulating Angiogenesis;39
7.5;V. PI3K/PTEN Controls Angiogenesis through Increasing HIF-1 and VEGF Expression;44
7.6;VI. The Downstream Signaling Molecules Mediated by PI3K/PTEN in Regulating Tumor Growth and Angiogenesis;46
7.7;VII. Inhibition of PI3K Signaling Pathway for Cancer Treatment and Prevention;50
7.8;VIII. Concluding Remarks;57
7.9;References;58
8;Chapter 3: Tumor Dormancy and Metastasis;78
8.1;I. Introduction-The Clinical Problem;79
8.2;II. Experimental Studies of Tumor Dormancy;85
8.3;III. Clinical Approaches to Metastasis and Dormancy;90
8.4;IV. Future Implications;99
8.5;References;100
9;Chapter 4: Histone Demethylases and Cancer;114
9.1;I. Introduction;114
9.2;II. Histone Methylation and Chromatin Structure;119
9.3;III. Histone Methylation and Cancer;137
9.4;IV. Histone Demethylases as Therapeutic Targets;162
9.5;V. Concluding Remarks;163
9.6;References;164
10;Chapter 5: Sirtuins and p53;182
10.1;I. Introduction;182
10.2;II. Sirtuins and Disease;188
10.3;III. Sirtuins Levels and Activity in Cancer Cells;189
10.4;IV. Sustained SirT1 Depletion and Genomic Instability;190
10.5;V. Small-Molecule Sirtuin Inhibitors: Activity in Preclinical Models for Cancer;191
10.6;VI. Sirtuin Inhibition and p53;193
10.7;VII. Discussion on Sirtuin Inhibition as a Therapeutic Approach;196
10.8;References;198
11;Chapter 6: Oxidative Stress and Lymphocyte Persistence: Implications in Immunotherapy;208
11.1;I. Introduction;209
11.2;II. Oxidative Stress;211
11.3;III. Lymphocyte Subsets, Immune Functions, and Persistence;214
11.4;IV. Mechanisms for Differential Susceptibility;220
11.5;V. Redox Regulation and Signaling;223
11.6;VI. Rescue of Lymphocytes from Oxidative Stress-Induced Apoptosis;226
11.7;VII. Future Clinical Developments to Improve Tumor Immunity by Prolonging the Life Span of Effector T Cells and NK Cells;227
11.8;VIII. Conclusion;229
11.9;References;229
12;Index;240
13;Color Plates;246
